exemestane + sacibertinib

This is a combination of two small molecule drugs, exemestane and sacibertinib. Exemestane is an oral steroidal aromatase inhibitor used primarily in the treatment of hormone receptor-positive breast cancer in postmenopausal women. It works by irreversibly binding to and inhibiting the aromatase enzyme, leading to decreased estrogen production, which slows or stops the growth of estrogen-dependent breast cancer cells[1][2][4]. Sacibertinib does not appear in any major drug databases or literature as of June 2025; it may be a typographical error, an investigational compound with no public data available, or a code name not yet widely recognized.